Burgess Hill, UK, 4th, November, 2008 – Roche in the UK has created a new website for children with diabetes designed to help young people with diabetes and their families learn more about the condition. Named Accu-Chek Teams, the site was launched in June to mark Diabetes Week 2008.
An interactive webtool entitled "Managing Your Diabetes" provides information for children and advice for parents on how diabetes is treated and controlled, as well as offering guidance on diet and exercise. This tool has also been very well received as a training aid for use by paediatric diabetes specialist nurses.
The site, which has received approx. 4,000 visits since its launch, also features a fun multiple-choice quiz, which combines trivia and health questions, a news and stories section, and message boards for kids and teens with diabetes, giving them the opportunity to share experiences and make friends online.
The new website forms part of Roche's ongoing support programme for children with diabetes. Roche Diagnostics is also pleased to be sponsors of the Juvenile Diabetes Research Foundation's (JDRF) new magazine for children in 2008.
For further information please visit: www.accu-chekteams.co.uk
Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world's biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, and is a market leader in virology. It is also active in other major therapeutic areas such as autoimmune diseases, inflammatory and metabolic disorders and diseases of the central nervous system. In 2007 sales by the Pharmaceuticals Division totalled 36.8 billion Swiss francs, and sales by the Diagnostics Division totalled 9.3 billion Swiss francs. Roche Diabetes Care posted 2007 sales of 3.2 billion Swiss francs. Roche has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai, and invested over 8 billion Swiss francs in R&D in 2007. Worldwide, the Group employs about 80,000 people. Additional information is available on the Internet at www.roche.com.
About Roche Diabetes Care
Roche Diabetes Care is a pioneer in the development of blood glucose monitoring systems and a global leader for diabetes management systems and services. For more than 30 years, the Accu-Chek brand has been committed to enable people with diabetes to live life as normal and active as possible as well as to help healthcare professionals manage their patients' condition in an optimal way. Today, the Accu-Chek portfolio offers people with diabetes and healthcare professionals innovative products and services and comprehensive solutions for convenient, efficient and effective diabetes management spanning from blood glucose monitoring through information management to insulin delivery. The Accu-Chek brand encompasses blood glucose meters, insulin delivery systems, lancing devices and data management systems. For more information please visit www.accu-chek.co.uk
All trademarks used or mentioned in this release are legally protected by law.
For further information please contact:
Phone: 01444 256000
|Return to the Top of This Page|
Last Updated: Wednesday November 05, 2014 21:27:37
This Internet site provides information of a general nature and is designed for educational purposes only. If you have any concerns about your own health or the health of your child, you should always consult with a physician or other health care professional.
This site is published by T-1 Today, Inc. (d/b/a Children with Diabetes), a 501c3 not-for-profit organization, which is responsible for its contents. Our mission is to provide education and support to families living with type 1 diabetes.
© Children with Diabetes, Inc. 1995-2018. Comments and Feedback.